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Effects of the new Histone Deacetylase Inhibitor, PXD101,
in Bladder Cancer
Hristos Z. Kaimakliotis, Marcia Wheeler, and Robert M. Weiss, Section of Urology,
Department of Surgery, Yale University, School of Medicine, New Haven, CT.
Histone deacetylase inhibitors (HDACIs) mediate gene expression and chromatin
assembly, and induce growth arrest and apoptosis of tumor cells, thus representing a new
strategy for human cancer therapy. Changes in apoptosis signaling pathways and the effect
on cell growth and cell-cycle arrest of a new HDACI, PXD101, on T-24 bladder cancer
cells form the basis of this study.
T-24 cells were incubated with PXD101 at varying concentrations and times, and
viable cell count and proliferation curves were constructed. Cell cycle analysis was
conducted with Fluorescent Activated Cell Sorting and changes in apoptosis signaling
proteins that were previously found to be regulated by survivin-siRNA in T-24 cells were
assessed by Western blot.
Treatment of T-24 bladder cancer cells with the HDAC inhibitor PXD101 causes a
profound decrease in cell growth and viability, a specific G2/M phase arrest and an
increase in apoptotic cells populations. PXD101 treatment also causes changes in upstream
mitochondrial apoptosis mediators, including TNFR1 and caspases 2 and 8, and
downstream apoptosis mediators, such as caspase 3 and survivin. PXD101 treatment of
tumor cells is associated with a profound decrease in survivin and caspases’ levels, and
with an increase in TNFR1 protein levels, both changes indicative of induction of apoptosis.
Therefore, the new HDACI PXD101, alone or in combination with inhibitors of
other tumor relevant factors and chemotherapies with complementary mechanisms of
action, shows promise for its use as a suitable new agent for bladder cancer treatment.

ACKNOWLEDGEMENTS
I first wish thank Dr. Robert Weiss, who has been my mentor and teacher ever
since I decided to become a urologist. I owe all of my successes, both in the laboratory
and in my pursuit of a career in urology, to his advice, support and friendship. I would
next like thank Marcia Wheeler, who guided me through every step of the conception,
planning, execution and summarizing of this project. Without her infinite patience, this
project would not have been possible. I also wish to thank Dr. David Rosenberg for
making my time in the laboratory thoroughly enjoyable. I owe thanks to the Yale
Medical School Office of Student Research, for awarding me the Yale Medical Student
Research Fellowship to make this possible. Finally, I would like to thank my parents,
Zack and Myroulla for their endless sacrifices and support the past four years.

Table of Contents:
Introduction......................................................................................................................... 1
Bladder Cancer................................................................................................................ 2
Findings....................................................................................................................... 4
Pathology .................................................................................................................... 5
Transitional Cell Carcinoma ....................................................................................... 6
Causes ......................................................................................................................... 7
Natural History............................................................................................................ 9
Staging and Treatment .............................................................................................. 10
Histone Deacetylase Inhibitors as a New Cancer Treatment........................................ 12
Histone Deacetylase Inhibitors and Bladder Cancer ................................................ 13
A new Histone Deacetylase Inhibitor, PXD101 ....................................................... 16
Statement of Purpose ........................................................................................................ 17
Materials and Methods...................................................................................................... 18
Results............................................................................................................................... 20
Cell Proliferation and Viable Cell Counts .................................................................... 20
FACS Analysis.............................................................................................................. 22
Western Blot Analysis .................................................................................................. 24
Discussion ......................................................................................................................... 28
References......................................................................................................................... 36

1

Introduction
A multicellular organism functions as a society, with individual cells organizing
into collaborative assemblies and reproducing by cell division through an elaborate set of
signals that serve as controls. Each cell rests, divides, differentiates or dies as needed for
the prosperity of the organism. Molecular disturbances that upset this harmony mean
trouble for such a society and in animals with countless cells and disturbances, mutations
are a constant challenge. A single mutation that goes unchecked may give rise to a
growing mutant clone of cells that will prosper at the expense of neighboring cells and in
the end, destroy the entire society.
Such is the recipe for cancer, and to this day, cancer accounts for nearly onequarter of deaths in the United States, exceeded only by heart disease. In 2003, there
were 556,902 cancer deaths in the US, Figure 1. The risk of an American male
developing cancer over his lifetime is one in two and approximately one in three women
in the United States will develop cancer over her lifetime.
Cause of Death

No. of
deaths

% of all
deaths

1.

Heart Diseases

685,089

28.0

2.

Cancer

556,902

22.7

3.

Cerebrovascular diseases

157,689

6.4

4.

Chronic lower respiratory diseases

126,382

5.2

5.

Accidents

109,277

4.5

6.

Diabetes mellitus

74,219

3.0

7.

Influenza and pneumonia

65,163

2.7

8.

Alzheimer disease

63,457

2.6

9.

Nephritis

42,453

1.7

34,069

1.4

10. Septicemia

Figure 1: United States Mortality Data, Leading Causes of Death for 2003 [1].
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Bladder Cancer
It is estimated that almost 1.4 million new cases of cancer were diagnosed in
2006. Of these, 61,420 cases were due to urinary bladder cancer, making it the fourth
most common and ninth most common site of new cancer diagnoses in men and women,
respectively. Bladder cancer is the second most common genitourinary tract cancer and
between 1985 and 2000, the number of bladder cancers diagnosed annually in the United
States increased by 33% [2, 3]. The incidence in men is nearly three times higher than in
women [3], and 1.5 times higher in whites than in African Americans. Incidence rates in
Hispanic Americans of each sex are roughly half those in whites [4].

Men
720,280
Prostate

33%

Women
679,510
31% Breast

Lung & bronchus 13%

12% Lung & bronchus

Colon & rectum

10%

11% Colon & rectum

Urinary bladder

6%

6%

Melanoma of skin

5%

Non-Hodgkin
lymphoma

4%

4% Non-Hodgkin
lymphoma

Kidney

3%

3%

Oral cavity

3%

3% Ovary

Leukemia

3%

2%

Urinary bladder

Pancreas

2%

2%

Pancreas

All Other Sites

18%

4%

Uterine corpus

Melanoma of skin
Thyroid

22% All Other Sites

Figure 2: 2006 Estimated US Cancer Incidence By Site and Sex. Data exclude basal
and squamous cell skin cancers [5].
It was estimated that in 2000 there were 12,200 bladder cancer deaths, 8100 men
and 4100 women, making bladder cancer the seventh most common cause of cancer
deaths in American men [3]. Bladder cancer accounts for 2.9% of all cancer deaths in
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men and 1.5% in women. Even though mortality rates have decreased since the 1970s
among African Americans and stabilized since the late 1980s among whites [6], an
estimated 13,060 deaths occurred in 2006, as shown in Figure 3. The 5-year relative
survival rate for bladder cancer is 83% for whites and 64% for African Americans. The
survival rate has improved somewhat since the 1970s, mainly due to earlier detection.

Figure 3: Types of cancers in United States, with incidence and resulting death rate.
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Findings
The most common presenting symptom of bladder cancer is painless hematuria,
which occurs in more than 85% of patients [7]. However, hematuria is often intermittent,
and the lack of hematuria does not rule out the presence of bladder cancer [8]. If an adult
has unexplained gross or microscopic hematuria, cystoscopic examination is warranted.
The symptom complex of bladder irritability and urinary frequency, urgency, and dysuria
is the second most common presentation and is usually associated with diffuse carcinoma
in situ or invasive bladder cancer. These symptoms almost never occur without at least
microscopic hematuria.
Other signs and symptoms of bladder cancer include flank pain from ureteral
obstruction, lower extremity edema and pelvic mass. Very rarely, patients present with
symptoms of advanced disease, such as weight loss and abdominal or bone pain.
Hepatomegaly and supraclavicular lymphadenopathy are signs of metastatic disease.
Pyuria may be present, either due to a concomitant infection or inflammation of the
urothelium around the tumor. Azotemia due to ureteral obstruction or anemia from
chronic blood loss also may be found.
Cytologic specimens from bladder washings may allow tumor detection and are
useful in screening patients or assessing response to treatment. Urine cytology is more
sensitive in patients with high-grade tumors or carcinoma in situ, but even in patients
with high-grade tumors, cytology may be falsely negative in as many as 20%of cases.
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Pathology
Nearly all bladder cancers are of epithelial origin, with the vast majority being
transitional cell carcinomas. The urothelium of the normal bladder is three to seven layers
thick, with a basal cell layer and one or more layers of intermediate cells in between the
basal layer and the superficial basal layer. The most superficial layer is composed of
large, flat, umbrella cells and the entire urothelium rests on the lamina propria basement
membrane.
Epithelial hyperplasia describes an increase in the number of cell layers without
nuclear or architectural abnormalities, whereas urothelial metaplasia refers to a nontransitional epithelial appearance of the bladder lining, with associated squamous or
adenomatous metaplasia. Atypical hyperplasia is similar to epithelial hyperplasia, except
that there are also nuclear abnormalities and a partial derangement of the umbrella cell
layer [9]. The term dysplasia denotes epithelial changes that are intermediate between
normal urothelium and carcinoma in situ. Dysplastic cells have large, round, notched,
basally situated nuclei that do not exhibit the normal epithelial polarity. Dysplastic
epithelium does not have an increased number of cell layers or mitotic figures [7], but a
large portion of patients with moderate dysplasia tend to develop high-grade urothelial
cancer [10].
Carcinoma in situ may appear cystoscopically as a velvety patch of erythematous
mucosa, although it may be endoscopically invisible. It consists of a poorly differentiated
transitional cell carcinoma confined to the urothelium, Figure 4. Carcinoma in situ may
be asymptomatic or may produce severe symptoms of urinary frequency, urgency and
dysuria. Urine cytopathology is positive in 80% to 90% of patients with carcinoma in situ
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[11]. Carcinoma in situ is present in 25% or more of patients with high-grade superficial
tumors [9], and between 40 and 83% progress to muscle-invasive cancer[12]. It also is
present in 20 to 75% of high-grade muscle-invasive cancers [13]. About 20% of patients
treated with cystectomy for diffuse carcinoma in situ are found to have microscopic
muscle-invading cancer [14].

Figure 4: Carcinoma in situ [15].

Transitional Cell Carcinoma
The most common bladder cancers are transitional cell (TCC), squamous cell and
adenocarcinomas. More than 90% of bladder cancers are TCC, which exhibit an
increased number of epithelial cell layers with papillary foldings of the mucosa, loss of
cell polarity, abnormal cell maturation with increased nuclear-cytoplasmic ratio,
prominent nucleoli, clumping of chromatin and increased number of mitoses. TCC
manifests in a variety of patterns of tumor growth, including papillary, sessile,
infiltrating, nodular, mixed, and flat intraepithelial growth (carcinoma in situ).
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Approximately 70% of bladder tumors are papillary, 10% are nodular and 20% are
mixed.
No uniformly accepted grading system for TCC exists, but most systems are
based on the degree of anaplasia of tumor cells [16, 17]. A strong correlation exists
between tumor grade and stage [18], with most well-differentiated and moderately
differentiated tumors being superficial and most poorly differentiated tumors being
muscle invasive. There is a significant correlation between tumor grade and prognosis,
however, the correlation between tumor stage and prognosis is even stronger.

Nontransitional Cell Carcinomas
Squamous cell carcinoma accounts for only 5% of bladder cancers in Europe and
the United States [19, 20], but as much as 75% in Egypt, where Schistosoma
haematobium cystitis is causally related to the development of squamous cell carcinoma
of the bladder [21]. Adenocarcinomas account for less than 2% of primary bladder
cancers [20], and are prevalent in intestinal urinary conduits, augmentations, neobladders
and bladder exstrophy [22]. About 5% of all cases are mixed, and other epithelial cancers
include carcinoid, carcinosarcomas and melanomas. Rare nonepithelial cancers of the
bladder include pheochromocytomas, choriocarcinomas and mesenchymal tumors.

Causes
Chemical carcinogens have been implicated in the pathogenesis of bladder cancer,
but there are undoubtedly a large portion of cases with no obvious exposure to such
agents. Occupational exposure accounts for roughly 20% of bladder cancer cases in the
United States [23], and the latency period is around 30-50 years, with more intensive
exposures leading to shorter latency periods [24]. Most bladder carcinogens are aromatic
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compounds. Nevertheless, the list is non-exhaustive, from aniline dyes [25], to
combustion gases and soot from coal, chlorinated aliphatic hydrocarbons [26], dietary
nitrites and nitrates [27] and aldehydes used in the rubber and textile industries [28].
Although the mechanisms of carcinogenesis in the presence of inflammation are
not understood [29] there appears to be a clear association of inflammation and squamous
cell carcinoma of the bladder. Chronic cystitis in the form of severe, long-term infections
leads to an increased risk [30]. There also is an association with the presence of long-term
indwelling catheters, since 2-10% of paraplegics with long-term indwelling catheters
develop malignancy.

Cigarette smoking also has been reported to be significantly

associated with an increased risk of transitional and squamous cell bladder carcinomas
[31], leading to a fourfold higher incidence of bladder cancer compared to people who
have never smoked [32, 33], with the risk correlating with the number of pack years.
Use of cyclophosphamide leads to a ninefold increased risk of developing bladder
cancer [32], with a relatively short latent period between 6 and 13 years. These are high
grade and muscle infiltrating tumors at the time of diagnosis, with an equal incidence in
both sexes [34]. The urinary metabolite acrolein is believed to be the responsible agent
[35], and mesna, 2-mercaptoethanesulfonic acid, reduces the risk of bladder cancer in
patients who develop hemorrhagic cystitis [36].
Specific genetic associations are still unknown, but are likely to involve activation
of oncogenes or loss of function of tumor suppressor genes. Some of the most common
genetic abnormalities identified in bladder cancer include loss of chromosomes 11p or
17p, which map to the proto-oncogene c-ras and the tumor suppressor gene p53,
respectively[37].

9

Natural History
Malignant transitional cells invading the lamina propria and the muscularis
propria can gain access to blood vessels and lymphatics. Roughly 5% of patients with
well-differentiated or moderately differentiated superficial papillary cancer and
approximately 20% with high-grade superficial disease (including carcinoma in situ)
ultimately manifest vascular or lymphatic spread, indicating that many patients with
superficial malignancies have their initial lesion pathologically understaged and already
harbor muscle-invading disease [38].
In the United States, about 60% of all newly diagnosed bladder cancers are welldifferentiated or moderately differentiated, superficial papillary TCC [39]. The majority
of these patients develop tumor recurrences after endoscopic resection, with up to 25%
recurring as higher-grade tumors [13]. Approximately 10% of patients with superficial
papillary tumors subsequently develop invasive or metastatic cancer [11, 12], even after a
prolonged tumor-free remission of over 5 years [10]. 40% of newly diagnosed bladder
cancers are high-grade lesions, more than half of which are muscle invading or more
extensive at the time of diagnosis [39]. High-grade superficial tumors tend to recur and
develop invasive and metastatic disease far more frequently than low-grade tumors [38].
Most patients with occult metastases develop overt clinical evidence of distant
metastases within 1 year [40]. The common sites of metastases are liver, 38%, lung, 36%,
bone, 27%, adrenal glands, 21%, and intestine, 13% [15]. High grade disease also spreads
by implantation in abdominal wounds or denuded urothelium [41]. Despite advances in
treatment of systemic urothelial cancer, few patients with distant metastases survive 5
years [42].
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Staging and Treatment
Because tumor stage is important in determining therapy, accurate staging of
bladder cancer is desirable. The main staging system of bladder cancer, also termed
Tumor-Node-Metastasis system (TNM), has been revised and developed by the
International Union Against Cancer and the American Joint Committee on Cancer [43].
PRIMARY TUMOR (T)
Ta
Single, low grade, nonNoninvasive
recurrent
papillary
Multiple, high grade, or
carcinoma
recurrent
Tis Carcinoma in situ: flat tumor
T1
Tumor invades lamina propria
T2
T2a
T2b
T3
T3a
T3b
T4
T4a

Tumor invades muscle
Tumor invades superficial muscle
Tumor invades deep muscle (outer half)
Tumor invades perivesical fat
Microscopically
Macroscopically (extravesical mass)
Tumor invades prostate, uterus, vagina,
pelvic wall, or abdominal wall
Tumor invades prostate, uterus, vagina

Treatment Option
Complete Transurethral resection (TUR)
Complete TUR followed by intravesical BCG
or chemotherapy
Complete TUR followed by intravesical BCG
Complete TUR followed by intravesical BCG
or chemotherapy
Radical cystectomy
or
Neoadjuvant chemotherapy followed by radical
cystectomy
or
Radical cystectomy followed by adjuvant
chemotherapy
or
Neoadjuvant chemotherapy followed by
irradiation

T4b

Tumor invades pelvic or abdominal wall
NODAL INVOLVEMENT (N)
N0 No regional lymph node metastasis
N1 Metastasis in a single lymph node, 2 cm
or less in greatest dimension
N2 Metastasis in a single lymph node, more
than 2 cm but not more than 5 cm in
greatest dimension, or multiple lymph
nodes, none more than 5 cm in greatest
dimension
N3 Metastasis in a lymph node more than 5
cm in greatest dimension
DISTANT METASTASIS (M)
M0 No distant metastasis
M1
Distant metastasis

Systemic chemotherapy followed by selective
surgery or irradiation

Systemic chemotherapy followed by selective
surgery or irradiation

Table 1: TNM Staging System for Bladder Cancer
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Bladder cancer remains a therapeutic challenge, where cystectomy, systemic
chemotherapy, radiation, intravesical treatment or a combination of these comprise the
spectrum of interventions. Treatments begin from transurethral resection and intravesical
therapy of superficial bladder tumors, as indicated in Table 1, and include selective
surgical cystectomy procedures, before or after chemotherapy or irradiation for muscle
invasive disease.
Intravesical instillation with Bacillus Calmette-Guerin (BCG) has proven to be an
effective treatment for superficial bladder cancer and for CIS for the last twenty five
years, even though the exact mechanism of action remains unknown [44]. Mitomycin C,
an antibiotic that inhibits DNA synthesis, is equivalent to BCG for superficial disease in
terms of survival rates [45]. Radical cystectomy is the treatment of choice for muscleinvasive bladder cancer, however, only half of these patients will be cured by cystectomy
alone [46]. Systemic chemotherapy involves MVAC, methotrexate, vinblastine,
adriamycin and cisplatin, which has been the standard combination regimen for nearly
two decades. For locally advanced and metastatic bladder cancer, long-term survival is
rare. Average survival for patients receiving MVAC is less than 14 months, and
approximately 4% remain disease-free at 5 years [47]. Newer agents, such as
gemcitabine, have a single-agent response rate of approximately 25% [48].
Even though the mortality rates for bladder cancer have improved over the last
thirty years, it is estimated that 13,060 patients in 2006 succumbed of the disease. Current
forms of therapy for invasive tumors are limited and there has been little improvement
over the last two decades. These daunting statistics beckon for new and better treatment
modalities [49].
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Histone Deacetylase Inhibitors as a New Cancer Treatment
Evidence for epigenetic events associated with tumorigenesis centers around
DNA methylation and histone acetylation [50]. Post-translational modifications of
histones, such as acetylation, phosphorylation and methylation, play an important role in
chromatin structure and function and in the regulation of gene expression [51]. Histone
acetylation is regulated by two families of enzymes, histone acetyl transferases (HATs)
and histone deacetylases (HDACs), which catalyze, respectively, the addition or the
hydrolysis of acetyl groups to lysine residues of nucleosomal histones [52]. The opposing
actions of HATs and HDACs allow gene expression to be exquisitely regulated.
Histone hypo-acetylation is involved in the tumorigenesis of many malignancies,
and inhibition of HDACs poses as a new strategy in human cancer therapy. To date,
many HDAC inhibitors (HDACIs) have been developed and have been shown to be
potent inducers of tumor growth arrest, differentiation and apoptosis of tumor cells in
vitro and in cancer patients in phase I and II clinical trials [53]. Although the precise
mechanisms underlying these cellular responses to HDACIs have yet to be characterized,
HDACI efficacy may be due at least in part to suppression of cancer cell migration,
invasion, metastasis, blood supply and angiogenesis [53].
There are several structurally diverse classes of HDACIs. These include shortchain fatty acids, cyclic and non-cyclic hydroxamates, cyclic peptides or tetrapeptides,
benzamides, ketones and hybrids of hydroxamic acid and cyclic tetrapeptide. One of the
first known HDACI was sodium N-butyrate [54], a potent growth inhibitor and
differentiating agent for many tumor cell lines. During initial clinical trials, limited
efficacy was observed with some toxicity and Phase II clinical trials are still on-going.
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Phenylacetate and phenylbutyrate gave the same results, as well as the anti-epileptic
agent, valproic acid, which has been reported to delay the growth of primary breast
cancers and to act against metastases found in the lung [55]. However, all these
compounds are weak inhibitors, even in high concentrations and non-selective, with
pleiotropic effects [56].

Histone Deacetylase Inhibitors and Bladder Cancer
T-24 cells are poorly differentiated bladder urothelial cells, derived from an
invasive high-grade bladder tumor with metastatic potential [57]. When treated with
several HDACIs, such as suberoylanilide hydroxamic acid or Trichostatin A, T-24 cells
show changes in a core set of genes that are involved in cell cycle progression, DNA
synthesis and apoptosis [58]. Specific changes include an up-regulation of tumor
suppressor p21, an accumulation of cells in the G2/M phase of the cell cycle and a
decrease in survivin levels [59]. p21 is aberrantly expressed in bladder cancer [60] and
when activated, modulates survivin expression [61, 62].
Survivin is a member of the family of inhibitors of apoptosis proteins (IAP), and
is expressed in nearly all human carcinomas, including TCC, but not in terminally
differentiated adult tissues [63]. It is highly expressed in bladder cancer and bladder
cancer cell lines, but not in normal urothelium or in cultured urothelial cells [64, 65], and
its expression in bladder tumors correlates with abbreviated survival [64]. Furthermore,
the presence of survivin protein and mRNA in urine [66] correlates with the presence of
TCC and that when measured in subjects following intravesical BCG or mitomycin C
treatment, survivin may serve as a marker for recurrent disease [67].
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As a pilot study in the Weiss lab, T-24 cells were treated with valproic acid, a
relatively weak HDACI with inhibitor activity in the millimolar range, to assess effects
on the IAP survivin (Justin Cohen, unpublished results). Incubation of T-24 cells with 10
mM valproic acid for 24 and 48 hrs caused a 65 and 57% decrease in cell proliferation,
respectively, and reduced survivin protein levels by approximately 50% relative to actin
protein levels at 0.1 mM (Figure 5).

Figure 5: Effect of Valproic acid on survivin levels in T-24 cells at 24 hours.
Given the importance of this IAP, the Weiss lab and others have investigated the
possibility of a new cancer treatment strategy for TCC by reducing the levels of survivin
using RNA interference [68]. This is a process by which a 20-25 nucleotide small
interference RNA (siRNA) can lead to specific gene silencing by forming a RNAinduced silencing complex with double-stranded RNA. Because survivin is important in
bladder cancer tumorigenesis, this new technique has implications for gene therapy of
TCC. This led to siRNA-mediated down-regulation of survivin in two bladder cancer cell
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lines, which was associated with reduced viability, a specific G2/M arrest, the induction
of apoptosis, the occurrence of multi-nucleated cells and an increase in cytosolic
cytochrome c, a marker of mitochondrial damage. The Weiss group also investigated the
effects of survivin-siRNA on T-24 bladder cancer cells using microarray analysis of a set
of 114 apoptosis related genes. Significant decreases were noted in 14 genes, as shown in
Table 2.
Inhibitors of Apoptosis (IAPs)
BIRC5
SURVIVIN
TNF receptors & genes related to NF-κB signaling
TNFRSF25 DR3/Apo-1/cd95 (TNF RECEPTOR SUPERFAMILY MEMBER 25)
TNFRSF1A TNFR1 (TNF RECEPTOR SUPERFAMILY MEMBER 1A)
LYMPHOTOXIN β RECEPTOR(TNF RECEPTOR SUPERFAMILY MEMBER 3)
LTBR
TRADD
TNFRSF1A-ASSOCIATED VIA DEATH DOMAIN
Caspases and related genes
CARD10
CASPASE RECRUITMENT DOMAIN FAMILY MEMBER 10
CASP4
CASPASE-4, APOPTOSIS-RELATED CYSTEINE PROTEASE
CASP2
CASPASE-2, APOPTOSIS-RELATED CYSTEINE PROTEASE ICH-2
Akt/PKB & related genes
Akt /PKB Akt / PKB (v-Akt MURINE THYMOMA VIRAL ONCOGENE HOMOLOGUE 1)
ABL1
c-Abl (v-Abl ABELSON MURINE LEUKEMIA VIRAL ONCOGENE HOMOLOGUE 1)
Bcl-2 related genes
BCL2L11
BCL2-LIKE11 (APOPTOSIS FACILITATOR, BimL)
BCL2L13 BCL2-LIKE 13 (APOPTOSIS FACILITATOR)
BNIP1
NIP-1 (BCL2/ADENOVIRUS E1B 19 kDa INTERACTING PROTEIN 1)
BCL2L12 BCL2-LIKE 12 (APOPTOSIS FACILITATOR)
BAK1
Bak (BCL2 -ANTAGONIST/KILLER 1)
Housekeeping genes
GAPD
GAPDH
ACTB
BETA- ACTIN

Survivin siRNA/
Scramble SiRNA ratio
0.02
0.18
0.40
0.46
0.74
0.17
0.31
0.31
0.14
0.20
0.15
0.19
0.19
0.21
0.29
0.85
0.97

Table 2: Changes in apoptotic gene products after treatment of T-24 cells with
survivin-siRNA for 72 hours.
Downregulation of survivin in T-24 cells using survivin-siRNA is associated with a
decreased cell growth, a specific G2/M arrest, an increase in cytochrome-c release and
altered production of genes related to apoptosis, including four TNF receptors [69], three
caspases, and the Bcl-2 related gene, BAK1 [65].
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A new Histone Deacetylase Inhibitor, PXD101
PXD101 is a new hydroxamate HDACI developed by TopoTarget Prolifix in the
UK and Curagen in the US. PXD101 was found to inhibit HDAC activity in HeLa
extracts with an IC50 value of 27 nM. It also inhibited HDAC activity in various cell
lysates from ovary, colon, lung or breast with an IC50 in the 9–100 nM range. Antitumor
activity at a dose of 10 mg/kg daily was observed in xenografts of the human ovarian cell
line A2780, with no effect on body weight or apparent toxicity to the mice at ≤40 mg/kg.
Antitumor activity was also noted [70] in cell lines relatively resistant to current
cytotoxic drugs. PXD101 is well tolerated in rodents and non-rodents and orally
bioavailable in dogs. PXD101 entered Phase I clinical trials at the end of 2003 [71].
Synergism with cis-platin and 5-Fu has also been reported [72].

Figure 6: Histone Deacetylase Inhibitor, PXD101
No significant improvement in the treatment of bladder cancer has occurred in the
past two decades and therefore new modalities of treatment are needed. Survivin is highly
expressed in TCC, and its down-regulation causes profound changes in mitosis and
apoptosis, which may be related to changes in TNF receptors. HDAC inhibitors inhibit
the growth of bladder cancer cells, and also downregulate survivin and other antiapoptotic proteins in cancer cells. Therefore, we propose to study the effects of PXD101
on survivin levels in T-24 bladder cancer cells, as the chemopreventative role of this new
HDACI may involve down-regulation of survivin and other apoptotic signaling proteins.
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Statement of Purpose
Bladder cancer remains a therapeutic challenge as current forms of therapy for
invasive tumors are limited. Daunting statistics beckon for new and better treatment
modalities.

HDACIs mediate gene expression and chromatin assembly, and induce

growth arrest and apoptosis of tumor cells, thus representing a new strategy for human
cancer therapy. HDACIs inhibit the growth of bladder cancer cells, and also
downregulate survivin and other anti-apoptotic proteins in cancer cells. Survivin is
highly expressed in TCC and down-regulation of survivin causes profound changes in
mitosis and apoptosis. Therefore, changes in apoptosis signaling pathways and the effect
on cell growth and cell-cycle arrest of a new HDACI, PXD101, on T-24 bladder cancer
cells form the basis of this study.
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Materials and Methods
All experiments and data analysis were conducted by Hristos Z. Kaimakliotis.
Materials:

Anti-survivin

polyclonal

antibody

was

purchased

from

NovusBiologicals, Inc, Littleton, CO. Anti-caspase-8 monoclonal antibodies was
purchased from Cell Signaling Technology, Beverly, MA. Anti-actin goat polyclonal and
anti-TNFR1 monoclonal antibodies were purchased from Santa Cruz Biotechnology.
Anti-caspase-3 polyclonal antibody was purchased from R&D Systems, Inc. Anticaspase-2 polyclonal antibody was purchased from BD Pharmingen Bioscience, San
Diego CA. Anti-Bak polyclonal antibody was purchased from Upstate, Charlottesville,
VA. Peroxidase-conjugated affiniPure F(ab’)2 fragment donkey anti-rabbit IgG and rat
anti-mouse antibodies were purchased from Jackson ImmunoResearch Laboratories,
West Grove, PA.
Preparation of cells treated with PXD101: T-24 cells were plated on 6 well
plates in McCoy’s media with serum and glutamate. Cells were treated after 24 hours,
when they were 30-50% confluent. Cells were incubated with PXD101 for up to 72
hours, then trypsinized, treated with trypan blue and counted or prepared for Western blot
or FACS cell sorting.
FACS of propidium iodide (PI) treated cells: Trypsinized cells were washed
with PBS and fixed with 95% ethanol. Two hours prior to cell sorting, ethanol was
removed after centrifugation. Since RNA also binds PI, cells were treated with 400 μg
RNAse type 1A (Sigma, St. Louis, MO) at 37°C for 30 minutes, followed by PI (50
μg/ml) for 45 minutes (4°C). Cells were sorted and analyzed with ModFit to determine
DNA content.
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Western blot analysis: After removal of media, 20 mmol/L Tris buffer (pH 7.4)
containing 1 mmol/L EDTA, 1 mmol/L EGTA, 1% triton X-100, phosphatase and
protease inhibitors, was added to culture wells to lyse the cells (10 minutes, 4°C). Then,
2x SDS sample buffer with 5% β-mercaptoethanol was added, cells were scraped and
collected. Pairs of samples were normalized for each time point and concentration of
PXD101, based on actin quantification determined after Western blot. To normalize the
samples, standard loading volumes were used and samples were subjected to Western
blot analysis and normalized volumes were determined by adjusting loading volumes
with respect to actin immunoreactivity of the protein bands on the resulting blot.
For all Western blots, after separation of proteins by SDS-PAGE, proteins are
transferred to nitrocellulose membranes. After incubation with the appropriate primary
and

secondary

antibodies,

immunoreactive

proteins

were

detected

using

chemiluminescence (ECL, Amersham Biosciences, Uppsala, Sweden). Band densities
from photographic film of the blot were quantified using digital image analysis (Eastman
Kodak Company, Rochester, NY).
Cell proliferation assay: Cell proliferation in the presence and absence of the
HDACI, PXD101 was measured by the cleavage of the tetrazolium salt WST-1 to
formazan by mitrochondrial dehydrogenases (EMD Bioscience, Darmstadt, Germany).
Statistics: For each experiment a PXD101 concentration curve was constructed,
using vehicle in control samples. Results of at least 3 different experiments performed in
duplicate were expressed as a mean % change over control ± SEM. Significance was
determined by ANOVA (p<0.05).
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Results
Changes in apoptosis signaling pathways and the effect on cell growth and cellcycle arrest of the new HDACI, PXD101, on T-24 bladder cancer cells form the basis of
this study and results are presented below.

Cell Proliferation and Viable Cell Counts
T-24 cells were incubated with PXD101 at varying concentrations and times, and
proliferation and viable cell count curves were constructed. In the presence of 5 μM
PXD101 for 48 hours, T-24 cells exhibited a 56.7% ± 4.2 decrease in proliferation
(Figure 7).
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Figure 7: T-24 cell inhibition at 48 hours in presence of PXD101.
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In the presence of 5 μM PXD101 for 72 hours, T-24 cells exhibited a 64.8% ± 3.2 decrease in
proliferation (Figure 8).
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Figure 8: T-24 cell inhibition at 72 hours in presence of PXD101.
Viable cell counts of T-24 cells incubated for 24 and 48 hours with 5 μM
PXD101 decreased by 30.6% ± 4.8 and 89.0% ± 3.0, respectively. The IC50 of PXD101
for proliferation and viable cell counts was approximately 1 μM (Figure 9).
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Figure 9: T-24 viable cell counts in presence of PXD101 for 24 hrs and 48 hrs.
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FACS Analysis
Cell cycle analysis was conducted with FACS. Treatment of T-24 bladder cancer
cells with PXD101 (2 and 5 μM, 48 hrs) increased apoptotic cells (sub-G1 cells) 1.3 and
2.3 fold, respectively (Figure 10). Apoptotic cells appeared as a distinct population of
decreased size and cell density, as expected.

Figure 10: T-24 bladder cancer cells FACS scatter plots of control (left) vs. treated
(right, 5 μM PXD 101 for 48 hours).

The untreated gated control population was used for cell-cycle population analysis
and comparison, and cell distributions. All changes reported in Table 3 are significant. T24 bladder cancer cells treated with PXD101 (1, 2 and 5 μM, 48 hrs) decreased G1 phase
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cells by 41-54% and increased S and G2/M phase cells 2.5-3.5 fold (Figure 11). No
significant changes in cell cycle distribution were noted at 12 or 24 hours.
Time
(hr)

0μM PDX101

1μM PDX101

2μM PDX101

5μM PDX101

Cell Cycle Changes over Control
G0/G1 phase
48
-41.2% + 3.8
-53.7% + 3.1
-53.9% + 0.9
S phase
48
+287.4%+127.4 +343.0%+125.7 +364.8%+124.3
G2/M phase
48
+250.5%+29.8 +271.3%+33.3
+321.5%+39.1
Cell Cycle Distribution
G0/G1 phase
48
84.2.0%+2.9
49.3%+2.2
40.1% + 2.0
38.9% + 1.9
S phase
48
5.5% + 1.8
14.4%+0.5
17.5% + 1.4
18.8% + 1.8
G2/M phase
48
7.9% + 1.3
27.9%+2.7
28.8% + 2.6
33.6% + 3.6
Table 3: FACS analysis of cell cycle distribution and changes in T-24 bladder cancer
cells treated with PXD101.
Figure 11 shows a representative FACS cell-cycle histogram, comparing treated
vs. untreated cells at 48 hours.

Figure 11: T-24 bladder cancer cells FACS cell-cycle histogram of untreated (red)
vs. treated (green, 5 μM PXD 101 for 48 hours).
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Western Blot Analysis
Changes in apoptosis signaling proteins that the Weiss laboratory previously
found to be regulated by survivin-siRNA in T-24 cells (See Table 2) were assessed by
Western blot in this study for effects by HDACI PXD101 in T-24 cells. These proteins
included survivin, caspases 2, 3 and 8, BAK1 and TNFR1. Actin levels were used to
normalize across varying concentrations, as it remains unchanged during induction of
apoptosis. Representative blots of each protein assessed are shown in Figure 12 and all
protein level changes are shown in Figures 14 & 15 and are reported in Table 4.

Actin
43kDa
Survivin
16kDa
Caspase 2
48kDa
Caspase 3
32kDa
Caspase 8
43kDa
BAK1
30kDa
TNFR1
55kDa

Conc (μM)

0

0.01

0.05

1.0

2.0

5.0

Figure 12: Representative western blots showing actin, survivin, caspases 2, 3 and 8,
BAK1 and TNFR1 levels in T-24 bladder cancer cells treated with PXD101 for 48
hours (experiments were repeated three times for a total n=6).
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The caspases were analyzed using the higher molecular weight pro-caspase band,
even though the active protein is the lower molecular cleaved product. One antibody is
used for each pro-caspase/caspase pair in question, and although directed at the procaspase band, binds both at different rates. The presence of cleaved (activated) caspase
was visualized for all three caspases, but only at long film exposures, which deterred its
quantitative analysis due to over-exposure and appearance of non-selective binding
(Figure 13). Decrease in the levels of pro-caspase with the concomitant increase of
cleaved activated product indicates up-regulation of caspase pathways and induction of
apoptosis.

Figure 13: Representative western blots of pro-caspases 2, 3 and 8 with their
respective activated cleaved products in T-24 bladder cancer cells treated with
PXD101 for 48 hours (experiments were repeated three times for a total n=6).
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All changes in protein levels are shown in Figures 14 & 15 and are reported in
Table 4. Incubation of T-24 cells with PXD101 for 24 hours decreased protein levels of
survivin by 30-60% between 0.5-5 μM, and pro-caspase 2 levels by 43.7 ± 11.9% at 5
μM. The protein levels of TNFR1 and pro-caspase 8 were increased with low
concentrations of PDX101 at 24 hours (TNFR1: 112.9 ± 26.1% and 77.9 ± 13.9% at 0.1
and 0.5 μM; pro-caspase 8: 140.7 ± 1.5%; 0.5 μM), whereas the protein levels of procaspase 3 and of the Bcl2 related protein, BAK1, showed no significant change at 24
hours (Figure 14).
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Figure 14: Changes in levels of apoptosis related proteins, survivin, caspases 2, 3
and 8, BAK1 and TNFR1, in T-24 cells treated with PXD101 at 24 hours (data was
generated by quantifying Western blots from three separate experiments, n=6).
As in the 24 hour experiment, incubation of T-24 cells with PXD101 for 48 hours
increased protein levels of TNFR1 by 123.0 ± 62.9% at the low concentration of 0.1 μM.
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Incubation with higher concentrations of PXD101 for 48 hours decreased the levels of all
the other proteins tested, as shown in (Figure 15).
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Figure 15: Changes in levels of apoptosis related proteins survivin, caspases 2, 3
and 8, BAK1 and TNFR1, in T-24 cells treated with PXD101 at 48 hours (data was
generated by quantifying Western blots from three separate experiments, n=6).
Time
0.1mM
0.5mM
1mM
2mM
5mM
(hr)
PDX101
PDX101
PDX101
PDX101
PDX101
BAK1
24
1.7% + 17.4
1.8% + 18.2
-7.8% + 16.1
2.3% + 10.0 -23.9% + 12.2
Caspase 3
24
5.4% + 15.8
22.3% + 11.1
7.8% + 13.8
1.0% + 10.3 -28.8% + 10.2
Caspase 2
24
10.0% + 0
0.5% + 0.1
-16.9% + 1.5 -18.3% + 5.4 -43.7% + 11.9
Caspase 8
24
22.1% + 3.8
140.7%+ 1.5 66.8% + 57.4 17.8%+ 22.6 -36.2% + 15.7
Survivin
24
1.4% + .08
-30.5% + 1.6
-47.1% + 7.0 -52.6% + 2.1 -59.8% + 5.7
TNFR1
24
112.9%+ 26.1 77.9% + 13.9 -19.5% + 25.9 0.8% + 26.2 -48.8% + 16.1
BAK1
48
5.7% + 6.7
5.6% + 7.3
-0.9% + 5.7
-4.3% + 7.0
-38.8% + 8.8
Caspase 3
48
-9.4% + 7.4
-26.6% + 7.7
-46.8% + 3.8 -50.2% + 9.9 -60.2% + 8.8
Caspase 2
48
-8.0% + 3.3
-16.0% + 13.7 -38.0% + 17.7 -40.3% + 6.2 -73.1% + 15.6
Caspase 8
48
10.0% + 7.9
18.5% + 14.7 -20.1% + 14.9 -42.0% +13.5 -79.6% + 11.6
Survivin
48
-0.5% + 5.6
-2.4% + 15.0 -62.6% + 10.5 -90.2% + 3.2 -94.7% + 3.0
TNFR1
48
123.0%+ 62.9 75.0% + 47.8 37.0% + 34.3 -4.0% + 35.8
-100% + 1.0
Table 4: Relative change in apoptosis proteins survivin, BAK1, TNFR1, caspases 2, 3 and 8,
in T-24 cells treated with PXD101 at 24 and 48 hours (red indicates significant changes, n=6).
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Discussion
Even though the mortality rates for bladder cancer have improved over the last
thirty years, it is estimated that over thirteen thousand patients succumbed to the disease
in 2006. Current forms of therapy for invasive tumors are limited and there has been little
improvement over the last two decades. These daunting statistics beckon for new and
better treatment modalities [49].
Histone deacetylase inhibitors (HDACIs) represent a new strategy for human
cancer therapy, as they mediate gene expression and chromatin assembly, and induce
growth arrest and apoptosis of tumor cells. HDACIs also down-regulate survivin, which
is highly expressed in TCC. The Weiss group has previously shown that down-regulation
of survivin in T-24 cells using survivin-siRNA is associated with a decreased cell growth,
a specific G2/M arrest and altered production of genes related to apoptosis, including
TNF receptors [69], caspases, and Bcl-2 related genes [65]. Cytochrome c release into the
cytoplasm, the central gate in the activation of apoptosis, was also increased, indicative of
mitochrondrial damage [65].
Many of these apoptosis related changes have been reported by the use of several
HDACIs in various cancer cell lines. Therefore, changes in apoptosis signaling pathways
and the effect on cell growth and cell-cycle arrest of a new HDACI, PXD101, on T-24
bladder cancer cells formed the basis of this study. Western blot analysis of survivin,
caspases 2, 3 and 8, Bcl-2-antagonist/killer 1 (BAK1) and TNF receptor superfamily
member 1 (TNFR1) was performed. These proteins were chosen for protein analysis
because of their high level of gene product expression in T-24 cells and their profound
down-regulation when T-24 cells are subjected to survivin-siRNA treatment [65].

29
In the presence of 5 μM of the new HDACI, PXD101 for 48 and 72 hrs, T-24
bladder cancer cells exhibited 57 and 65% decreases in proliferation, respectively. This
decrease in proliferation is greater than changes reported with use of other HDACIs,
including valproic acid and phenylbutyrate, at concentrations in this range [73]. Viable
cell counts at 24 and 48 hrs (5 μM) were also decreased by 31 and 89% respectively, and
the IC50 of PXD101 for proliferation and viable cell counts was approximately 1 μM at
48 hours. This is higher than results found in HeLa extracts with an IC50 value of 0.03
μM and various cell lysates from ovary, colon, lung and breast with an IC50 in the 0.1 μM
range [73]. Nonetheless, this relatively low IC50 of PXD101 compared to other agents
may allow it to be used at lower concentrations, with a lower side effect profile.
Although no changes in cell cycle distribution were noted at 12 or 24 hours,
treatment of T-24 cells with PXD101 for 48 hours at 2 and 5 μM increased apoptotic cells
(sub-G1 cells) 1.3 and 2.3 fold, respectively. Apoptotic cells appeared as a distinct
population of decreased size and cell density, as expected. These dying cells were
excluded from analysis of the rest of the cell-cycle phases to provide accurate comparison
between live cells of treated and control samples. PXD101 at 1, 2 and 5 μM for 48 hrs,
decreased G1 phase cells by 41-54% and increased S and G2/M phase cells between 2.53.5 fold. This indicates that mitosis is incomplete, with a specific arrest at the G2/M
phase. These results are consistent with other HDACIs’ activity and is in accord with the
arrest seen when survivin is down-regulated by treatment with survivin-siRNA in T-24
cells [65], hepatocellular carcinoma cells, human sarcoma cells [68] and HeLa cells [74].
As expected, the protein levels of survivin in T-24 cells treated with PXD101 are
decreased by 30-60% with 0.5-5 μM PXD101 at 24 hours, and by 62-94% with 1-5 μM
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PXD101 at 48 hours. These changes are consistent with survivin-siRNA and other
HDACI induced down-regulation of survivin [65], and lead to the apoptotic changes and
cell death described earlier, as the IAP is no longer exhibiting its effect in tumor cells.
On the other hand, the TNFR1 protein is dramatically up-regulated at 24 hours of
treatment with PXD101 at low concentrations. TNFR1 is increased 113 and 78% with 0.1
and 0.5 μM at 24 hours, and 123.0% at 48 hours with 0.1 μM PXD101. TNF is tumor
necrosis factor and increases in TNF receptors and related proteins are considered proapoptotic. Up-regulation of TNFR1 and its ligand TNFα, have been shown to occur when
apoptosis is induced in leukemic cell with the HDACI, depsipeptide (FK228) [75],
further demonstrating the efficacy of PXD101 as an anti-tumor agent.
Activation of the death domain containing receptors, TNF receptor superfamily, is
associated with activation of the caspase cascade, cytochrome c release, and apoptosis.
To activate TNF receptors, specific adaptor proteins such as FAS-associated death
domain (FADD) or receptor-interacting protein [RIP]-associated ICH-1/CED-3homologous protein with a death domain (RAIDD/CRADD) bind to ligand-bound
receptor complexes. Interaction between these adaptor proteins and the prodomain of
initiator caspases 2, 8 or 10 triggers sequestration-mediated auto-activation of these
caspases. These caspases, in turn, cleave and activate downstream caspases 3, 6, and 7
and trigger apoptosis (Figure 16, page 31).
Up-regulation of TNFR1 is reversed at higher concentrations of PXD101 and a
dramatic down-regulation of TNFR1 is observed. Several authors have described
increases in TNF receptors, ligands and related genes to be associated with induction of
apoptosis, but there is growing evidence to suggest that TNFα promotes tumor
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development and growth [76]. In a mouse model of metastatic colon adenocarcinoma,
TNFα promotes tumor growth [77] and mice deficient in TNFα are resistant to skin
carcinogenesis [78]. Furthermore, TNFR1 is the major mediator of TNFα-induced tumor
formation in skin tumors [79] and during liver carcinogenesis [80]. Thus, while the initial
decrease in TNFR1 induced at low concentrations of PXD101 may be considered as part
of an activation of apoptotic pathways, the latter increase in TNFR1 at higher PXD101
concentrations may be pro- or anti-apoptotic in T-24 bladder cancer cells.

Figure 16: Signalling pathways in T-24 bladder cancer cells altered by survivinsiRNA. Red lettering indicates that either message or protein levels were modified
by survivin-siRNA.
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Similar to TNFR1 protein regulation, pro-caspase 8 levels are up-regulated at low
concentrations of PXD101 and down-regulated at high PXD101 concentrations. Caspase
8 is an upstream caspase associated with a number of apoptotic pathways including
TNFR1, APO2L/TRAIL and FASL. It is believed that the TNFR1-induced pro-apoptotic
signaling pathway requires the formation of two signaling complexes. A rapidly formed
plasma membrane bound complex is composed of TNFR1, TRADD, RIP, TRAF2, and cIAP1 and triggers a NF-κB response, but no apoptosis. A second complex, which lacks
TNFR1 but includes FADD and pro-caspases 8 and 10, subsequently forms in the
cytoplasm. The complex containing pro-caspase 8 initiates apoptosis, provided that the
NF-κB signal from complex I fails to induce the expression of anti-apoptotic proteins
such as FLIPL. FLIPL is an inhibitor of caspase 8 [81]. Thus, up-regulation of both
TNFR1 and caspase 8 may be essential for apoptosis.
Along with caspase 8, caspase 2 function as an upstream modulator that can
trigger mitochondrial apoptotic pathways and release of cytochrome c [82]. Caspase-2 is
required for the translocation of BAX/BAK1 to the mitochondria as well as release of
mitochondrial proteins, which leads to apoptosis. Caspase 3 is a downstream effector
caspase and is involved in Fas-mediated apoptosis. Decrease of pro-caspase levels with
concomitant increase in lower molecular weight activated cleaved product is indicative of
caspase pathway activation and induction of apoptosis.
A profound decrease in protein levels of pro-caspases 2, 3 and 8 at higher
PXD101 concentrations is noted, with a concomitant appearance of respective cleaved
products, further supporting the induction of apoptosis in tumor cells. The cleaved
products are only visualized at long film exposures though, deterring quantitative analysis
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of cleaved products. The initial up-regulation of pro-caspase 8 at low PXD101
concentration may be due to an initial response by T-24 cells prior to cleavage to the
activated product, since caspase 8 is an upstream modulator.
The Bcl-2 family of proteins governs mitochondrial outer membrane
permeabilisation and can be either pro-apoptotic or anti-apoptotic, and can induce or
inhibit the release of cytochrome c in to the cytosol, which activates caspase-9 and
caspase-3, leading to apoptosis. The protein levels of BAK1, a Bcl-2 related protein
which promotes the release of cytochrome c, are decreased at high concentrations in T-24
cells after treatment with PXD101. This is similar to our previous results, where
expression of many Bcl gene products is altered in T-24 cells after treatment with
survivin-siRNA. Survivin-siRNA treatment down-regulates mRNA of apoptosis
facilitators, including BCL2-L11, -L12, -L13, BAK1 and BNIP1 (NIP-1, BCL interacting
protein 1). BAK1 protein is initially up-regulated by survivin-siRNA, but by 72 hours
BAK1 levels decrease. BNIP3, which induces both apoptotic and necrotic death, is also
down-regulated in prostate carcinoma cells after treatment with ribosome-mediated
inhibition of survivin expression. The complex regulation of these pro-and anti- apoptosis
molecules by PXD101 and survivin-siRNA suggests that the relative concentrations of
these molecules and the time course of activation or synthesis of these proteins may
determine if a cell lives or dies [83].
In summary, T-24 cells treated with PXD101 are characterized by decreased
growth and large numbers of cells undergoing apoptosis and arresting in G2/M phase of
the cell-cycle. PXD101 treatment is also associated with changes in upstream
mitochondrial apoptosis mediators, including TNFR1 and caspases 2 and 8, and
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downstream apoptosis mediators, such as caspase 3, BAK1 and survivin. PXD101
treatment of tumor cells is associated with a profound decrease in survivin and procaspases’ levels, and with an increase in TNFR1 protein levels, both changes indicative
of induction of apoptosis. BAK1 levels remain unchanged until high concentrations of
the HDACI. This decrease in BAK1 levels, and in fact of all apoptosis related proteins at
very high PXD101 concentrations, may be the result of PXD101 treatment or the T-24
cells’ response to that treatment, such as generalized cell death with decreased protein
synthesis. The down-regulation of survivin may cause T-24 cells to up-regulate TNF
receptors and cleave pro-caspases in order to preserve their apoptotic phenotype.
HDACIs have shown profound results in initiating tumor regression and
symptomatic improvement in some heavily pre-treated patients at an advanced stage who
have experienced multiple relapses. This regression has been achieved with a surprisingly
low side-effect profile and a wide therapeutic index [84]. The impressive anti-tumor
activity of HDACIs and their lack of toxicity at doses that effectively inhibit tumor
growth strongly support these agents as a suitable molecular target for anticancer drug
development. Therefore, the new HDACI PXD101, alone or in combination with
inhibitors of other tumor relevant factors and with chemotherapies with complementary
mechanisms of action, shows promise for its use as a suitable new agent for cancer
treatment.
This is the second report indicating up-regulation of TNFR1 with the use of any
HDACI and the first to our knowledge that describes an initial increase in protein levels
of apoptotic related proteins, only to be followed by a decrease in these levels. Future
work on this project will involve investigating the effects of this new HDACI, PXD101,
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using real time RT-PCR to assess mRNA levels of the apoptosis-related proteins
analyzed above. An ELISA assay of the TNRF1 ligand, TNFα, will also be conducted on
experiment media, to assess whether there is change in levels of this signaling molecule
to further support our findings. A manuscript is currently in preparation to report these
results and an abstract has been accepted to be presented at the national meeting of the
Society of Genitourinary Surgeons. In addition, our lab has developed transgenic mice
that over-express bladder specific survivin [85]. These mice demonstrate increased
bladder inflammation and respond to a bladder carcinogen with accelerated tumor
formation and shortened survival. The effects of PXD101 in these mice will be tested to
determine if they have altered susceptibility to HDACIs and increased survival rates.
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